Erratum: T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery (Gene Therapy (2006) vol. 13 (1480-1492) 10.1038/sj.gt.3302801);T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery

Gene Therapy

Volumn 13, Issue 20, 2006, Pages 1480-1492

  Swan, C H ^a,b   Buhler B ^a   Tschan, M P ^a   Barbas III, C F ^b   Torbett, B E ^a,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Department of Molecular Biology ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAD PROTEIN; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL GROWTH; CELL INTERACTION; CELL ISOLATION; CELL LINE; CELL PROTECTION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; INFECTION RESISTANCE; LIVER; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROVOCATION TEST; T LYMPHOCYTE; THYMOCYTE; THYMUS; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM; VIRUS INACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745941234     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302902     Document Type: Erratum

References (81)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-1958.
2. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
4. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 200; 177: 99-111.
5. Kozak SL, Platt EJ, Madani N, Ferro Jr FE, Peden K, Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997; 71: 873-882.
6. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
7. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
8. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
9. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
10. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
11. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352: 866-870.
12. Martin MP, Dean M Smith MW, Winkler C, Gerrard B, Michael NL et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-1911.
13. Yang AG, Bai X, Huang XF, Yao C, Chen S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997; 94: 11567-11572.
14. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 203; 100: 183-188.
15. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 2000; 1: 244-254.
16. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas III CF. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 2000; 97: 805-810.
17. Anderson J, Akkina R. HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005; 2: 1.
18. Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ et al. Protecting from R5-tropic HIV: Individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Therapy 2004; 11: 1627-1637.
19. Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
20. Arrighi JF, Pion M, Garcia E, Escola JM van Kooyk Y, Geijtenbeek TB et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 2004; 200: 1279-1288.
21. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992; 257: 383-387.
22. Gummuluru S, KewalRamani VN, Emerman M. Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover. J Virol 2002; 76: 10692-10701.
23. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004; 103: 2170-2179.
24. Lore K, Smed-Sorensen A, Vasudevan J, Mascola JR, Koup RA. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 2005; 201: 2023-2033.
25. Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 1997; 51: 257-283.
26. Konopka K, Duzgunes N. Expression of CD4 controls the susceptibility of THP-1 cells to infection by R5 and X4 HIV type 1 isolates. AIDS Res Hum Retroviruses 2002; 18: 123-131.
27. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997; 94: 1925-1930.
28. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96: 5215-5220.
29. Jamieson BD, Zack JA. In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998; 72: 6520-6526.
30. McCune JM. Development and applications of the SCID-hu mouse model. Semin Immunol 1996; 8: 187-196.
31. Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Datema R et al. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother 1996; 40: 755-762.
32. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, Chen IS et al. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993; 363: 732-736.
33. Berkowitz RD, Alexander S, Bare C, Linquist-Stepps V, Bogan M, Moreno ME et al. CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol 1998; 72: 10108-10117.
34. Bonyhadi ML, Moss K, Voytovich A, Auten J, Kalfoglou C, Plavec I et al. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 1997; 71: 4707-4716.
35. Pedroza-Martins L, Gurney KB, Torbett BE, Uittenbogaart CH. Differential tropism and replication kinetics of human immunodeficiency virus type 1 isolates in thymocytes: Coreceptor expression allows viral entry, but productive infection of distinct subsets is determined at the postentry level. J Virol 1998; 72: 9441-9452.
36. Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 2005; 11: 823-842.
37. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: Novel gene therapy approaches for AIDS. Gene Therapy 2005; 12: 467-476.
38. Kurre P, Anandakumar P, Harkey MA, Thomasson B, Kiem HP. Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration. Mol Ther 2004; 9: 914-922.
39. Gummuluru S, Kinsey CM, Emerman M. An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 2000; 74: 10882-10891.
40. Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother 2005; 49: 3474-3482.
41. Shaheen F, Collman RG. Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 2004; 17: 7-16.
42. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902-913.
43. Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH et al. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Hum Gene Ther 1999; 10: 1453-1467.
44. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
45. Mwau M, McMichael AJ. A review of vaccines for HIV prevention. J Gene Med 2003; 5: 3-10.
46. Kutilek VD, Sheeter DA, Elder JH, Torbett BE. Is resistance futile? Curr Drug Targets Infect Disord 2003; 3: 295-309.
47. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 215-221.
48. Park-Wyllie LY, Phillips EJ. Challenges of adherence management in human immunodeficiency virus pharmacotherapy. Can J Clin Pharmacol 2003; 10: 189-195.
49. Richman DD. HIV chemotherapy. Nature 2001; 410: 995-1001.
50. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3: 23-36.
51. Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911-4919.
52. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-1172.
53. Este JA. Virus entry as a target for anti-HIV intervention. Curr Med Chem 2003; 10: 1617-1632.
54. Segal DJ, Goncalves J, Eberhardy S, Swan CH, Torbett BE, Li X et al. Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem 2004; 279: 14509-14519.
55. Steinberger P, Sutton JK, Rader C, Elia M, Barbas III CF. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 2000; 275: 36073-36078.
56. Berson JF, Doms RW. Structure-function studies of the HIV-1 coreceptors. Semin Immunol 1998; 10: 237-248.
57. Choe H, Martin KA, Farzan M, Sodroski J, Gerard NP, Gerard C. Structural interactions between chemokine receptors, gp120 Env and CD4. Semin Immunol 1998; 10: 249-257.
58. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997; 71: 6305-6314.
59. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999; 274: 9617-9626.
60. Oppermann M. Chemokine receptor CCR5: Insights into structure, function, and regulation. Cell Signal 2004; 16: 1201-1210.
61. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909.
62. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
63. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
64. Goldstein H, Pettoello-Mantovani M, Anderson CM, Cordelier P, Pomerantz RJ, Strayer DS. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue. J Infect Dis 2002; 185: 1425-1430.
65. Marasco WA, LaVecchio J, Winkler A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 1999; 231: 223-238.
66. Vetrugno V, Cardinale A, Filesi I, Mattei S, Sy MS, Pocchiari M et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem Biophys Res Commun 2005; 338: 1791-1797.
67. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417: 95-98.
68. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78: 2790-2807.
69. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99: 395-400.
70. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203: 35-40.
71. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P et al. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV 1. J Virol 1995; 69: 3712-3720.
72. Wu L, Martin TD, Carrington M, KewalRamani VN. Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. Virology 2004; 318: 17-23.
73. Halene S, Wang L, Cooper RM, Bockstoce DC, Robbins PB, Kohn DB. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 1999; 94: 3349-3357.
74. Aviles Mendoza GJ, Seidel NE, Otsu M, Anderson SM, Simon Stoos K, Herrera A et al. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model. Mol Ther 2001; 3: 565-573.
75. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
76. Agarwal M, Austin TW, Morel F, Chen J, Bohnlein E, Plavec I. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 1998; 72: 3720-3728.
77. Auten J, Agarwal M, Chen J, Sutton R, Plavec I. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10: 1389-1399.
78. Kurre P, Morris J, Thomasson B, Kohn DB, Kiem HP. Scaffold attachment region-containing retrovirus vectors improve long-term proviral expression after transplantation of GFP-modified CD34+ baboon repopulating cells. Blood 2003; 102: 3117-3119.
79. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72: 5085-5092.
80. Gallay P, Stitt V, Mundy C, Oettinger M, Trono D. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 1996; 70: 1027-1032.
81. Mielke C, Kohwi Y, Kohwi-Shigematsu T, Booe J. Hierarchical binding of DNA fragments derived from scaffold-attached regions: Correlation of properties in vitro and function in vivo. Biochemistry 1990; 29: 7475-7485.